Personal epigenetic 'signatures' found consistent in prostate cancer patients' metastases
In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic "signatures" across all metastatic tumors in each patient. The discovery of the ...
Cancer
Jan 23, 2013 |
not rated yet |
0
|
Sickle cells show potential to attack aggressive cancer tumors
By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed ...
Cancer
Jan 09, 2013 |
5 / 5 (4) |
0
|
Study suggests gene variation may shape bladder cancer treatment
(Medical Xpress)—Patients who have inherited a specific common genetic variant develop bladder cancer tumors that strongly express a protein known as prostate stem cell antigen (PSCA), which is also expressed in many pancreatic ...
Cancer
Dec 27, 2012 |
5 / 5 (1) |
0
|
World-first tissue study could re-shape future of advanced prostate cancer treatment
The first-ever comprehensive study of prostate cancer tissue has revealed a completely new gene network driving the disease in patients who have stopped responding to standard hormone treatment, according ...
Cancer
Dec 21, 2012 |
not rated yet |
0
Game changing diagnostic and prognostic prostate cancer genetic tests revealed
Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant ...
Cancer
Dec 20, 2012 |
not rated yet |
0
Preventing prostate cancer through androgen deprivation may have harmful effects
Mice deficient in PTEN in the prostate developed stable precancers. Androgen deprivation promoted progression to invasive prostate cancer. Patients with PTEN-deficient prostate precancers may not benefit from androgen deprivation ...
Cancer
Dec 20, 2012 |
not rated yet |
0
|
Cancer study overturns current thinking about gene activation
(Medical Xpress)—A new Australian study led by Professor Susan Clark from Sydney's Garvan Institute of Medical Research shows that large regions of the genome – amounting to roughly 2% – are epigenetically activated ...
Cancer
Dec 18, 2012 |
5 / 5 (1) |
0
|
Researchers identify enzyme linked to prostate cancer
Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic ...
Cancer
Dec 18, 2012 |
not rated yet |
0
|
Adoptive cell transfer: New technique could make cell-based immune therapies for cancer safer, more effective
A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development ...
Cancer
Dec 16, 2012 |
5 / 5 (2) |
0
|
Researchers find new culprit in castration-resistant prostate cancer
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They ...
Cancer
Dec 13, 2012 |
not rated yet |
0
|
FDA OKs expanded use of prostate cancer drug
(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food ...
Medications
Dec 10, 2012 |
not rated yet |
0
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
The population of the United States is getting older, due not only to aging boomers but also to a four-year increase in life expectancy from 1990 to 2010. An aging population means increased diagnosis of prostate cancer. ...
Cancer
Dec 04, 2012 |
not rated yet |
0
Clinical trial targets advanced prostate cancer
Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.
Cancer
Dec 03, 2012 |
5 / 5 (1) |
0
Clinical trial hits new target in war on breast cancer
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...
Cancer
Dec 03, 2012 |
5 / 5 (2) |
0
|
Researchers develop novel treatment for prostate cancer
(Medical Xpress)—The work of a team of Wake Forest researchers developing a novel drug for prostate cancer treatment is featured on the cover of the Nov. 26 issue of the Journal of Medicinal Chemistry.
Cancer
Nov 29, 2012 |
5 / 5 (2) |
0
